Launch fatigue

Competition for new US exchange-traded fund listings is heating up, with Nasdaq launching a new incentive scheme for market-makers in July. But with similar schemes already in place at the New York Stock Exchange and American Stock Exchange, will it make a difference? Jayne Jung reports


Have you ever wanted a transparent way to invest in the orthopaedic repair medical device sector? Or how about the autoimmune-inflammation pharmaceutical industry? If your answer to either of these questions is yes, then you're in luck. These are the niche sectors that New York-based financial products firm XShares hopes to target with its HealthShares exchange-traded fund (ETF) series.

The autoimmune-inflammation pharmaceutical ETF began trading on the New York Stock Exchange (NYSE) on March 9

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact or view our subscription options here:

You are currently unable to copy this content. Please contact to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to View our subscription options

You need to sign in to use this feature. If you don’t have a account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here